CD274 and esophageal adenocarcinoma: Nivolumab plus chemotherapy significantly improved OS and progression-free survival (PFS) compared with chemotherapy alone in patients with a PD-L1 CPS of five or more as well as in patients with a PD-L1 CPS of one or more and all randomly assigned patients, which suggested that nivolumab plus chemotherapy as a promising treatment regimen for patients with advanced GEJ, or esophageal adenocarcinoma.